{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:50:13Z","timestamp":1762188613641,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005485","name":"American College of Cardiology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005333","name":"Center for Social Inclusion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.atherosclerosis.2020.05.014","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T11:38:11Z","timestamp":1592307491000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial"],"prefix":"10.1016","volume":"305","author":[{"given":"Suvasini","family":"Lakshmanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandana","family":"Shekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Kinninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraj","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afiachukwu","family":"Onuegbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajad","family":"Hamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Birudaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavanya","family":"Cherukuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dailing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sion K.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.014_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.05.014_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.05.014_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?","volume":"96","author":"McLaughlin","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"9539","key":"10.1016\/j.atherosclerosis.2020.05.014_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.05.014_bib5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/eurheartj\/ehi186","article-title":"High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial","volume":"26","author":"Olsson","year":"2005","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2020.05.014_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2006.04.006","article-title":"Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation","volume":"98","author":"Wolfram","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2020.05.014_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9841","key":"10.1016\/j.atherosclerosis.2020.05.014_bib8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2020.05.014_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/HCO.0000000000000211","article-title":"HDL-cholesterol and cardiovascular disease: rethinking our approach","volume":"30","author":"Siddiqi","year":"2015","journal-title":"Curr. Opin. Cardiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.05.014_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11886-017-0940-0","article-title":"HDL cholesterol metabolism and the risk of CHD: new insights from human genetics","volume":"19","author":"Vitali","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.014_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcct.2011.01.007","article-title":"Rationale and design of the CONFIRM (COronary CT angiography EvaluatioN for clinical outcomes: an InteRnational multicenter) Registry","volume":"5","author":"Min","year":"2011","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.014_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.22856","article-title":"Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg\/dL) on statin therapy: rationale and design of the EVAPORATE study","volume":"41","author":"Budoff","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.014_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvz329","article-title":"Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography","volume":"116","author":"Lakshmanan","year":"2020","journal-title":"Cardiovasc. Res"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2020.05.014_bib14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/clc.22746","article-title":"Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression","volume":"40","author":"Osawa","year":"2017","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.014_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.atherosclerosis.2016.11.004","article-title":"Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: a propensity-score matching study","volume":"255","author":"Nakanishi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.014_bib16","doi-asserted-by":"crossref","first-page":"427s","DOI":"10.3945\/jn.114.202424","article-title":"Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with metabolic syndrome in a prospective randomized double-blind study","volume":"146","author":"Matsumoto","year":"2016","journal-title":"J. Nutr."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.014_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2013.08.019","article-title":"Effect of statin treatment on coronary plaque progression - a serial coronary CT angiography study","volume":"231","author":"Zeb","year":"2013","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2020.05.014_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2020.05.014_bib19","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.05.014_bib20","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/ATVBAHA.118.307026","article-title":"Translating evidence of HDL and plaque regression","volume":"38","author":"Di Bartolo","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2020.05.014_bib21","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/j.jacc.2018.10.034","article-title":"Is RCT (reverse cholesterol transport) ready for an RCT (randomized controlled trial)?","volume":"72","author":"Nambi","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.05.014_bib22","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2020.05.014_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"Jama"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2020.05.014_bib24","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.atherosclerosis.2020.05.014_bib25","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"9260","key":"10.1016\/j.atherosclerosis.2020.05.014_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2020.05.014_bib27","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2003-030242","article-title":"The emergence of the metabolic syndrome with menopause","volume":"88","author":"Carr","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2020.05.014_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11936-019-0760-1","article-title":"Coronary computed tomography angiography: enhancing risk stratification and diagnosis of cardiovascular disease in women","volume":"21","author":"Karnib","year":"2019","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2020.05.014_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16071165","article-title":"Cardiovascular disease and the female disadvantage","volume":"16","author":"Woodward","year":"2019","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.05.014_bib30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/01.CIR.99.9.1165","article-title":"Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland","volume":"99","author":"Jousilahti","year":"1999","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2020.05.014_bib31","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":"High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2020.05.014_bib32","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.014_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.05.014_bib34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/00325481.2017.1385365","article-title":"Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?","volume":"129","author":"Nelson","year":"2017","journal-title":"Postgrad. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.05.014_bib35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.014_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2020.05.014_bib37","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.014_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.014_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jjcc.2017.09.001","article-title":"Nonfasting TG\/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target?","volume":"71","author":"Kiyosue","year":"2018","journal-title":"J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.014_bib40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2261-12-70","article-title":"Effect of statin therapy on the progression of coronary atherosclerosis","volume":"12","author":"Tian","year":"2012","journal-title":"BMC Cardiovasc. Disord."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020302823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020302823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:17Z","timestamp":1762187117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020302823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":40,"alternative-id":["S0021915020302823"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.014","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}